Novo Nordisk Plans Oral Ozempic Launch in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy NVO?
Source: seekingalpha
- Oral Drug Launch: Novo Nordisk plans to launch its oral GLP-1 receptor agonist Ozempic in Q2 2026, following the successful rollout of Wegovy, which is expected to meet the growing demand for oral diabetes medications.
- FDA Approval of New Name: The FDA has approved Ozempic as the name for oral semaglutide doses of 1.5 mg, 4 mg, and 9 mg, further solidifying Novo Nordisk's leadership in diabetes treatment.
- Market Demand Response: A senior executive noted that Ozempic's recognition has led to increased patient inquiries about oral options, with Rybelsus having been available since 2019, demonstrating the company's responsiveness to market needs.
- Label Expansion Application: Novo Nordisk has submitted a supplemental drug application to the FDA seeking to expand Ozempic's dosage to 25 mg, with a decision expected by year-end, which will enhance the competitiveness of its product line.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.480
Low
42.00
Averages
54.67
High
70.00
Current: 36.480
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Analysis Challenges Medicare's Weight Loss Drug Coverage Costs
- Annual Spending Forecast: Researchers from Vanderbilt University estimate that covering Novo Nordisk's Wegovy and Ozempic could result in annual spending between $3.9 billion and $4.8 billion, significantly exceeding government expectations and potentially straining Medicare budgets.
- Limited Savings: Although negotiated drug prices are projected to save approximately $933 million in the first year, this only covers 4.4% of the estimated 12.4 million Medicare beneficiaries eligible for the drugs, highlighting the limitations of the coverage scope.
- Potential Insurer Pushback: The authors note that Medicare plans may be reluctant to accept the trade-off of expanding obesity-indication coverage for lower per-fill prices due to potential budget implications, which could delay or alter Medicare policies.
- Policy Impact Assessment: The findings of this study may provoke pushback from Medicare insurers, further influencing future coverage policies for obesity drugs, especially in a tight budget environment.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Trump Administration Plans New Tariffs on Pharmaceuticals
- New Tariff Policy: The Trump administration is preparing to impose new tariffs on pharmaceutical companies that have not struck price reduction deals, with patented drugs facing a potential 100% tariff, which could significantly increase costs and impact drug pricing.
- Exemption Pathways: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating agreements with the administration, aiming to encourage domestic manufacturing while potentially reshaping drug supply chains.
- Scope of Impact: Since November, over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have secured three-year tariff exemptions through agreements with Trump, indicating a strong governmental stance on drug pricing that may alter competitive dynamics in the industry.
- Future Tariff Plans: The draft outlines a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could have profound implications for the pharmaceutical sector's long-term strategies amid increasing global market competition.
See More
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Analysis Challenges Medicare's Weight Loss Drug Coverage Costs
- Annual Spending Forecast: Researchers from Vanderbilt University estimate that covering Novo Nordisk's Wegovy and Ozempic could result in annual spending between $3.9 billion and $4.8 billion, significantly exceeding government expectations and potentially straining Medicare budgets.
- Limited Savings: Although negotiated drug prices are projected to save approximately $933 million in the first year, this only covers 4.4% of the estimated 12.4 million Medicare beneficiaries eligible for the drugs, highlighting the limitations of the coverage scope.
- Potential Insurer Pushback: The authors note that Medicare plans may be reluctant to accept the trade-off of expanding obesity-indication coverage for lower per-fill prices due to potential budget implications, which could delay or alter Medicare policies.
- Policy Impact Assessment: The findings of this study may provoke pushback from Medicare insurers, further influencing future coverage policies for obesity drugs, especially in a tight budget environment.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Trump Administration Plans New Tariffs on Pharmaceuticals
- New Tariff Policy: The Trump administration is preparing to impose new tariffs on pharmaceutical companies that have not struck price reduction deals, with patented drugs facing a potential 100% tariff, which could significantly increase costs and impact drug pricing.
- Exemption Pathways: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating agreements with the administration, aiming to encourage domestic manufacturing while potentially reshaping drug supply chains.
- Scope of Impact: Since November, over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have secured three-year tariff exemptions through agreements with Trump, indicating a strong governmental stance on drug pricing that may alter competitive dynamics in the industry.
- Future Tariff Plans: The draft outlines a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could have profound implications for the pharmaceutical sector's long-term strategies amid increasing global market competition.
See More
